- Home
- DTSS vs ATHA Comparison
DTSS vs ATHA Comparison
Compare DTSS & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- ATHA
- Stock Information
- Founded
- DTSS 2014
- ATHA 2011
- Country
- DTSS China
- ATHA United States
- Employees
- DTSS N/A
- ATHA N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- DTSS Technology
- ATHA Health Care
- Exchange
- DTSS Nasdaq
- ATHA Nasdaq
- Market Cap
- DTSS 17.6M
- ATHA 16.8M
- IPO Year
- DTSS N/A
- ATHA 2020
- Fundamental
- Price
- DTSS $1.95
- ATHA $4.23
- Analyst Decision
- DTSS
- ATHA
- Analyst Count
- DTSS 0
- ATHA 0
- Target Price
- DTSS N/A
- ATHA N/A
- AVG Volume (30 Days)
- DTSS 39.1K
- ATHA 32.0K
- Earning Date
- DTSS 11-12-2025
- ATHA 11-07-2025
- Dividend Yield
- DTSS N/A
- ATHA N/A
- EPS Growth
- DTSS N/A
- ATHA N/A
- EPS
- DTSS N/A
- ATHA N/A
- Revenue
- DTSS $71,616,820.00
- ATHA N/A
- Revenue This Year
- DTSS N/A
- ATHA N/A
- Revenue Next Year
- DTSS N/A
- ATHA N/A
- P/E Ratio
- DTSS N/A
- ATHA N/A
- Revenue Growth
- DTSS 198.70
- ATHA N/A
- 52 Week Low
- DTSS $1.63
- ATHA $2.20
- 52 Week High
- DTSS $3.10
- ATHA $8.26
- Technical
- Relative Strength Index (RSI)
- DTSS 46.29
- ATHA 68.05
- Support Level
- DTSS $1.88
- ATHA $3.78
- Resistance Level
- DTSS $1.98
- ATHA $4.30
- Average True Range (ATR)
- DTSS 0.08
- ATHA 0.23
- MACD
- DTSS -0.00
- ATHA -0.06
- Stochastic Oscillator
- DTSS 57.14
- ATHA 90.06
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.